文献速递间质性肺疾病

间质性肺疾病患者的共病与死亡率:一项基于人群的研究

Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study.
PubMed 文献 · Respirology · 2017-12-18

该研究利用丹麦国家患者登记系统识别1998至2010年间首次诊断间质性肺疾病(ILD)的患者,并按1:4匹配背景人群对照,评估共病负担(Deyo-Charlson共病指数,DCcs)对死亡率的影响。共纳入10 629例ILD患者,丹麦ILD发病率为17.6/10万(95%CI:16.5-18.7)。ILD患者共病(DCcs≥1)比例30%高于对照12%(P<0.001),5年生存率56.0%低于对照84.0%,死亡风险比男性3.82、女性3.85。

要点

  • ILD患者共病负担显著高于普通人群(30% vs 12%,P<0.001)。
  • ILD患者5年生存率仅56.0%,死亡风险约为匹配对照的3.8倍。
  • 共病负担越重,两组生存率均下降,但ILD与对照的死亡率差距趋于缩小。

核心结论

  • ILD患者在所有DCcs水平上生存均受损,但共病负担增加倾向于缩小与对照的死亡率差距。

研究设计与样本

  • 基于丹麦国家患者登记系统(DNPR)的全国性人群队列研究。
  • 纳入1998至2010年间首次诊断ILD的患者10 629例,按1:4匹配背景人群对照。
  • 采用Deyo-Charlson共病指数(DCcs)评估共病负担,Kaplan-Meier法评估生存,Cox比例风险模型估计死亡风险比(HRR)。

主要发现

  • 丹麦ILD发病率为17.6/10万(95%CI:16.5-18.7),患者平均年龄72岁,女性占45.6%。
  • ILD患者共病(DCcs≥1)比例为30%,对照组为12%(P<0.001)。
  • ILD患者5年生存率为56.0%(95%CI:54.6-56.6),对照组为84.0%(95%CI:83.7-84.4)。
  • 以匹配对照为参照,ILD患者死亡HRR男性为3.82(95%CI:3.63-4.02),女性为3.85(95%CI:3.62-4.09)。
  • DCcs=0时5年生存率ILD为61%、对照为87%;DCcs=2时ILD为41%、对照为58%。

临床怎么用

  • 临床应重视ILD患者的共病评估,共病负担是死亡风险的重要分层因素。
  • ILD患者即使共病少,死亡风险仍显著高于一般人群,需加强随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Co-morbidities are frequent among patients with interstitial lung diseases (ILD). The objective of this study was to investigate their impact on mortality. METHODS: We used the Danish National Patient Registry (DNPR) to identify all patients with a first-time diagnosis of ILD between 1998 and 2010. Patients with ILD were matched 1:4 with controls from the background population. The burden of co-morbidity was assessed using the Deyo-Charlson co-morbidity score (DCcs). Mortality risks were assessed using Kaplan-Meier survival curves, and hazard rate ratios (HRR) for death were estimated using Cox proportional hazards regression models. RESULTS: We identified 10 629 patients with ILD with a corresponding incidence estimate of ILD in Denmark of 17.6 per 100 000 inhabitants (95% CI: 16.5-18.7). Mean age was 72 years and 45.6% of the patients were females. Co-morbidity (DCcs ≥ 1) was present in 30% of the ILD patients and 12% of the controls (P < 0.001). The 5-year survival was 56.0% (95% CI: 54.6-56.6) among ILD patients and 84.0% (95% CI: 83.7-84.4) among controls. HRR for death among patients with ILD was 3.82 for males (95% CI: 3.63-4.02) and 3.85 for females (95% CI: 3.62-4.09) with matched controls as reference. Decreasing survival was seen with increasing DCcs for both groups. The 5-year survival for DCcs = 0 was 61% for ILD and 87% for controls compared with 41% versus 58% for DCcs = 2. CONCLUSION: Survival was impaired for patients with ILD for all levels of the DCcs, although increasing burden of co-morbidity tended to close the mortality gap.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Hilberg O, Bendstrup E, Løkke A, et al. Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study. Respirology. 2017. PMID: 29251396. doi:10.1111/resp.13234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。